Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J de Bono

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 21, 2014
Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trialJ McCready, A W Chow, M D Lowe, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repairT R Shenoy, G Boysen, M Y Wang, et al.
Investigational New Drugs|April 30, 2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studiesA Omlin, R J Jones, R van der Noll, et al.
Molecular Cancer|March 23, 2022
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancerC E Fletcher, L Deng, F Orafidiya, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 21, 2014
Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trialJ McCready, A W Chow, M D Lowe, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2010
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerL Shan, L Ambroisine, J Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repairT R Shenoy, G Boysen, M Y Wang, et al.
Investigational New Drugs|April 30, 2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studiesA Omlin, R J Jones, R van der Noll, et al.
Molecular Cancer|March 23, 2022
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancerC E Fletcher, L Deng, F Orafidiya, et al.
Pageof 5